ShortageWatch RxUS drug shortage tracker, built on FDA data

← All shortages

Crinecerfont Capsule shortage

To Be Discontinued  1 presentations · 1 manufacturers · first FDA posting 2026-04-28 · last update 2026-04-28

Manufacturers: Neurocrine Biosciences, Inc.

Stated reasons (per FDA): Not stated

📬 Get weekly shortage updates by email

Presentations

PresentationManufacturerStatusReasonNotes (FDA)Dates
Crenessity, Capsule, 25 mg (NDC 70370-5025-1)Neurocrine Biosciences, Inc.To Be Discontinued
 —Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).Posted 04/28/2026
Updated 04/28/2026
Discontinued 04/28/2026

Source: FDA Drug Shortages Database · raw openFDA records

Get the weekly shortage roundup: a free email of FDA shortage changes (open form)